Physician profile
Stephanie D Devaney
NPI 1861747149
$7,382.90
in general payments reported to CMS, 2019-2025
41 companies · $3,158 in 2025
The $3,158 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $462 · 2023: $1,094 · 2024: $2,668 · 2025: $3,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,848 · Education: $72.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,848.37 |
| Education | $72.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $962.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $919.03 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $685.26 | 2021-2025 | Evenity, Repatha, Prolia |
| Dexcom, INC. | $668.64 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $575.06 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $360.67 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $327.72 | 2023-2025 | |
| Abbvie INC. | $303.58 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.86 | 2021-2025 | |
| Sequel Med Tech, LLC | $233.02 | 2025 | Twiist |
| Abbott Laboratories | $209.26 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $169.13 | 2021-2024 | Minimed 780g |
| Corcept Therapeutics | $165.46 | 2023-2025 | Korlym |
| Recordati_rare_diseases_inc. | $160.05 | 2023-2025 | Isturisa, Signifor Lar |
| Antares Pharma, INC. | $158.99 | 2021-2025 | Xyosted |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $137.81 | 2021-2025 | Unithroid |
| Mannkind Corporation | $121.29 | 2023-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $114.14 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $89.40 | 2021-2025 | Tymlos |
| Madrigal Pharmaceuticals | $88.57 | 2025 | Rezdiffra |
| Insulet Corporation | $75.74 | 2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $73.62 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $57.66 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Acella Pharmaceuticals, LLC | $48.80 | 2024-2025 | NP Thyroid 60 |
| Beta Bionics, INC. | $45.61 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Endo USA, INC. | $37.39 | 2024-2025 | Aveed |
| Endo Pharmaceuticals INC. | $36.10 | 2024 | Aveed |
| Boston Scientific Corporation | $31.41 | 2025 | General - Pain Management |
| Rhythm Pharmaceuticals, INC. | $30.89 | 2025 | Imcivree |
| Alexion Pharmaceuticals, INC. | $29.85 | 2025 | Strensiq |
| Verity Pharmaceuticals INC. | $28.60 | 2025 | Tlando |
| Kyowa Kirin, INC. | $25.66 | 2024 | Crysvita |
| Chiesi USA, INC. | $23.09 | 2024 | Myalept |
| Pfizer INC. | $22.71 | 2025 | |
| Ibsa Pharma INC. | $21.47 | 2025 | Tirosint, Flector, Licart |
| Avvisto Therapeutics, LLC | $20.99 | 2025 | Cycloset |
| Halozyme INC | $18.80 | 2023 | |
| Merck Sharp & Dohme LLC | $17.69 | 2021 | |
| Lifescan, INC. | $17.19 | 2021 | |
| Amarin Pharma, INC. | $16.91 | 2021 | |
| Tolmar, INC. | $13.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Devaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.